Mestag Therapeutics

Mestag Therapeutics is a clinical-stage immunotherapy company based in Cambridge, UK, developing new treatments for cancer and inflammatory diseases by targeting the understudied role of activated fibroblasts in immune responses. Its lead cancer program, MST-0312, is a targeted LTBR-agonist bispecific antibody designed to drive tertiary lymphoid structure (TLS) formation in solid tumors and is now in the Phase I STARLYS trial. Its inflammatory-disease program, M402, uses agonist antibodies against stromal inhibitory receptors for conditions including rheumatoid arthritis, inflammatory bowel disease, and lupus. Backed by GV, Mestag is a privately held biotech and does not currently publish a public API, developer portal, or machine-readable API surface.

Mestag Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Immunology, and Immunotherapy.

Mestag Therapeutics’ developer surface includes engineering blog, support, and 5 more developer resources.

🌐 Visit website 📡 Source on GitHub
11.9/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyLife SciencesBiotechnologyImmunologyImmunotherapyOncologyDrug DiscoveryInflammatory DiseaseAntibodiesCambridge UK

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 11.9/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 1.3 / 20
Commercial Clarity 2.1 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/mestag-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Mestag Therapeutics Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy

Company 4

The organization behind the API

Website
Website
 Blog
Blog
 LinkedIn
LinkedIn
 Twitter
Twitter

Source (apis.yml)

apis.yml Raw ↑ 
aid: mestag-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/mestag-therapeutics.png
name: Mestag Therapeutics
description: Mestag Therapeutics is a clinical-stage immunotherapy company based in Cambridge, UK, developing new treatments
  for cancer and inflammatory diseases by targeting the understudied role of activated fibroblasts in immune responses. Its
  lead cancer program, MST-0312, is a targeted LTBR-agonist bispecific antibody designed to drive tertiary lymphoid structure
  (TLS) formation in solid tumors and is now in the Phase I STARLYS trial. Its inflammatory-disease program, M402, uses agonist
  antibodies against stromal inhibitory receptors for conditions including rheumatoid arthritis, inflammatory bowel disease,
  and lupus. Backed by GV, Mestag is a privately held biotech and does not currently publish a public API, developer portal,
  or machine-readable API surface.
url: https://raw.githubusercontent.com/api-evangelist/mestag-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Life Sciences
- Biotechnology
- Immunology
- Immunotherapy
- Oncology
- Drug Discovery
- Inflammatory Disease
- Antibodies
- Cambridge UK
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.mestagtherapeutics.com/
- type: Blog
  url: https://www.mestagtherapeutics.com/news/
- type: Support
  url: https://www.mestagtherapeutics.com/contact/
- type: PrivacyPolicy
  url: https://www.mestagtherapeutics.com/privacy-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/mestag-therapeutics/
- type: Twitter
  url: https://twitter.com/Mestagtx/
- type: DomainSecurity
  url: security/mestag-therapeutics-domain-security.yml
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 1
  pass: local-v1